RIVAL-01
- Generic Name
- RIVAL-01
Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid Tumors
Phase 1
Terminated
- Conditions
- Cervical CancerSolid TumorMicrosatellite Stable Colorectal CancerCutaneous Squamous Cell CarcinomaMesotheliomaHPV Positive Oropharyngeal Squamous Cell CarcinomaRenal Cell CarcinomaOropharynx CancerMelanoma (Skin)
- Interventions
- First Posted Date
- 2020-03-09
- Last Posted Date
- 2025-04-23
- Lead Sponsor
- Turnstone Biologics, Corp.
- Target Recruit Count
- 27
- Registration Number
- NCT04301011
- Locations
- 🇺🇸
The Billings Clinic, Billings, Montana, United States
🇰🇷National Cancer Center, Ilsandong, Korea, Republic of
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath